FINWIRES · TerminalLIVE
FINWIRES

$SYRE

23 stories mentioning SYREUpdated 9d ago

Every FINWIRES story that references SYRE, newest first.

What are analysts saying about SYRE?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on SYRE?

Insider Trading

Spyre Therapeutics Insider Sold Shares Worth $2,480,529, According to a Recent SEC Filing

Heidy King-Jones, Chief Legal Officer and Corporate Secretary, on September 01, 2026, sold 28,399 shares in Spyre Therapeutics (SYRE) for $2,480,529. Following the Form 4 filing with the SEC, King-Jones has control over a total of 2,845 common shares of the company, with 2,845 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1636282/000163628226000111/xslF345X05/wk-form4_1788485651.xml

$SYRE
Insider Trading

Spyre Therapeutics Insider Sold Shares Worth $2,283,821, According to a Recent SEC Filing

Scott L Burrows, Chief Financial Officer, on September 01, 2026, sold 25,732 shares in Spyre Therapeutics (SYRE) for $2,283,821. Following the Form 4 filing with the SEC, Burrows has control over a total of 79,762 common shares of the company, with 79,762 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1636282/000163628226000109/xslF345X05/wk-form4_1788485622.xml

$SYRE
Insider Trading

Spyre Therapeutics Insider Sold Shares Worth $1,309,410, According to a Recent SEC Filing

Cameron Turtle, Director, Chief Executive Officer, on September 01, 2026, sold 15,000 shares in Spyre Therapeutics (SYRE) for $1,309,410. Following the Form 4 filing with the SEC, Turtle has control over a total of 552,540 common shares of the company, with 552,540 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1636282/000163628226000107/xslF345X05/wk-form4_1788485583.xml

$SYRE
Wire

Top Midday Decliners

Electromed (ELMD) Chief Executive Jim Cunniff plans to retire around April 2 after serving as president and CEO since 2023, it said late Tuesday, adding that the board plans to search for his successor.Shares declined 18%, with intraday trading volume rising to over 229,000 from a daily average of about 89,000.Greenland Mines (GRML) shares slumped 43% amid heavy trading after the company said it priced its public offering of 4 million shares for gross proceeds of about $20 million.Intraday trading volume catapulted to over 2.09 million from a daily average of about 174,000.Spyre Therapeutics (SYRE) said late Tuesday its experimental rheumatoid arthritis drug SPY072 failed to meet the company's internal performance threshold needed to justify further stand-alone development, prompting a halt of its monotherapy RA program.Shares dropped 14% as intraday trading volume rose to over 1.96 million from a daily average of about 1.25 million.Price: $32.20, Change: $-7.14, Percent Change: -18.15%

$ELMD$GRML$SYRE
Wire

Spyre's IBD Pipeline Remains Key Driver, Wedbush Says

Spyre Therapeutics' (SYRE) pipeline for inflammatory bowel disease remains key value driver after "disappointing" results in rheumatoid arthritis drug trial, Wedbush said in a Tuesday note."While we view the RA result as disappointing, we see limited impact to our core IBD-driven thesis," the report said.The note said valuation of the stock remains driven by SPY001/002/003 in IBD. Even excluding all non-ulcerative colitis indications, the stock's price target would remain at about $115, well above current trading levels, it added."We continue to view September SPY003 SKYLINE Part A UC data and SKYLINEUC Part B data in 2027 as the substantially more important catalysts for shares," the report said.Wedbush cut its price target to $123 from $130 while keeping its outperform rating.Price: $93.99, Change: $-13.37, Percent Change: -12.45%

$SYRE
Wire

Spyre Halts Stand-Alone Rheumatoid Arthritis Drug Development; Shares Fall After Hours

Spyre Therapeutics (SYRE) said its experimental rheumatoid arthritis drug SPY072 failed to meet the company's internal performance threshold needed to justify further stand-alone development, prompting the halt of its monotherapy RA program.The drug delivered statistically significant improvements over placebo on several efficacy measures and showed a tolerable safety profile with no drug-related serious adverse events, the company said Tuesday in a statement.Spyre said it will now evaluate SPY072 in combination regimens and in other autoimmune indications, with additional clinical readouts expected in Q4.Spyre shares fell 12% in after-hours trading.

$SYRE
Insider Trading

Spyre Therapeutics Insider Sold Shares Worth $2,404,190, According to a Recent SEC Filing

Jeffrey W. Albers, Director, on August 07, 2026, sold 23,000 shares in Spyre Therapeutics (SYRE) for $2,404,190. Following the Form 4 filing with the SEC, Albers has control over a total of 9,360 common shares of the company, with 9,360 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1636282/000163628226000102/xslF345X05/wk-form4_1786411908.xml

$SYRE
Wire

Spyre Therapeutics Launches Program, Mid-Stage Trial for Drug Combination to Treat Hidradenitis Suppurativa

Spyre Therapeutics (SYRE) said Monday that it has launched SPY772, a program that combines SPY072, a long-acting anti-TL1A antibody, and SPY007, a novel long-acting anti-IL-17A/F antibody in preclinical development.The program is designed to treat patients with Hidradenitis Suppurativa, which is a skin condition that causes painful lumps deep within the skin, Spyre said.The clinical-stage company said it has initiated a mid-stage proof-of-concept trial evaluating dual inhibition of TL1A and IL-17A/F to treat Hidradenitis Suppurativa. The study is expected to enroll 150 adults. Topline results are expected late next year or early 2028.Price: $104.61, Change: $-0.30, Percent Change: -0.29%

$SYRE
Insider Trading

Spyre Therapeutics Insider Sold Shares Worth $1,432,705, According to a Recent SEC Filing

Cameron Turtle, Director, Chief Executive Officer, on August 03, 2026, sold 15,000 shares in Spyre Therapeutics (SYRE) for $1,432,705. Following the Form 4 filing with the SEC, Turtle has control over a total of 567,540 common shares of the company, with 567,540 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1636282/000163628226000099/xslF345X05/wk-form4_1785979866.xml

$SYRE
Insider Trading

Spyre Therapeutics Insider Sold Shares Worth $1,307,000, According to a Recent SEC Filing

Scott L Burrows, Chief Financial Officer, on June 25, 2026, sold 15,000 shares in Spyre Therapeutics (SYRE) for $1,307,000. Following the Form 4 filing with the SEC, Burrows has control over a total of 97,994 common shares of the company, with 97,994 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1636282/000185332726000008/xslF345X05/wk-form4_1782523902.xml

$SYRE
Wire

Spyre Therapeutics Shares Fall After Director Sells $2 Million in Stock

Spyre Therapeutics (SYRE) shares were down more than 13% in Wednesday trading after a regulatory filing showed that director Michael Thomas Henderson sold 20,000 company shares for $2 million on Monday.Trading volume stood at more than 2.9 million shares against a daily average of about 1.3 million.Price: $84.27, Change: $-12.78, Percent Change: -13.17%

$SYRE
Insider Trading

Spyre Therapeutics Insider Sold Shares Worth $2,000,000, According to a Recent SEC Filing

Michael Thomas Henderson, Director, on June 22, 2026, sold 20,000 shares in Spyre Therapeutics (SYRE) for $2,000,000. Following the Form 4 filing with the SEC, Henderson has control over a total of 68,606 common shares of the company, with 68,606 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1636282/000163628226000084/xslF345X05/wk-form4_1782264740.xml

$SYRE
Wire

Update: Wedbush Raises Price Target on Spyre Therapeutics to $100 From $80 on Positive SPY002 Results, Maintains Outperform Rating

(Updated to include Wedbush commentary)Wedbush increased Spyre Therapeutics' (SYRE) price target to $100 from $80 after the company released first clinical efficacy results for SPY002 for induction in ulcerative colitis patients.The top-line results appear in-line with other members of the class, highlighting that the drug could work well in combination therapies, analysts led by David Nierengarten wrote in a Monday note.Spyre Therapeutics has an average rating of buy and mean price target of $96.07, according to analysts polled by FactSet.Price: $81.70, Change: $+0.91, Percent Change: +1.13%

$SYRE
Wire

Wedbush Raises Price Target on Spyre Therapeutics to $100 From $80, Maintains Outperform Rating

Spyre Therapeutics (SYRE) has an average rating of buy and mean price target of $96.07, according to analysts polled by FactSet.Price: $81.49, Change: $+0.70, Percent Change: +0.87%

$SYRE
Insider Trading

Spyre Therapeutics Insider Sold Shares Worth $5,952,050, According to a Recent SEC Filing

Michael Thomas Henderson, Director, on May 08, 2026, sold 80,000 shares in Spyre Therapeutics (SYRE) for $5,952,050. Following the Form 4 filing with the SEC, Henderson has control over a total of 88,606 common shares of the company, with 88,606 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1636282/000163628226000053/xslF345X05/wk-form4_1778290306.xml

$SYRE
Commodities

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday as Investors Turn to Corporate Earnings

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.1% and the actively traded Invesco QQQ Trust (QQQ) was 0.01% higher in Wednesday's premarket activity as investors shift focus from geopolitical risks to earnings updates.US stock futures were also higher, with S&P 500 Index futures up 0.1%, Dow Jones Industrial Average futures advancing 0.1%, and Nasdaq futures gaining 0.01%before the start of regular trading.US mortgage applications increased 1.8% in the week ended April 10 as a rise in refinancing tied to lower rates offset a slight decline in purchase activity, Mortgage Bankers Association data showed Wednesday.US import prices increased 0.8% in March, below expectations, as a surge in petroleum costs drove most of the gain, government data showed. Excluding fuel, import prices edged up 0.1%, missing forecasts and slowing from the prior month.The National Association of Home Builders sentiment reading for April is due to be released at 10 am ET, followed by weekly petroleum stocks data at 10:30 am ET.The Fed's Beige Book report is due to be released at 2 pm ET.Fed Vice Chair for Supervision Michelle Bowman is slated to speak on Wednesday.In premarket activity, bitcoin was down by 0.1%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was flat, the Ether ETF (EETH) advanced 0.9%, and Bitcoin & Ether Market Cap Weight ETF (BETH) rose 11.6%.Power Play:EnergyThe iShares US Energy ETF (IYE) gained 0.2%, while the State Street Energy Select Sector SPDR ETF (XLE) was down by 0.2%.DHT (DHT) stock was up more than 4% before Wednesday's opening bell after the company said it expects Q1 time charter equivalent earnings of $78,800 per day.Winners and Losers:ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was down 0.1% and the Vanguard Consumer Staples Index Fund ETF Shares (VDC) was flat. The iShares US Consumer Staples ETF (IYK) was inactive. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) gained 0.1%. The VanEck Retail ETF (RTH) was inactive, while the State Street SPDR S&P Retail ETF (XRT) was 0.1% higher.Stellantis (STLA) shares were up more than 2% pre-bell after the company said its Q1 estimated consolidated shipments totaled 1.4 million units, up 12% from a year earlier.Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) advanced 0.1%, the Vanguard Health Care Index Fund (VHT) was up 0.7%, while the iShares US Healthcare ETF (IYH) was flat. The iShares Biotechnology ETF (IBB) was inactive.Spyre Therapeutics (SYRE) stock was up more than 2% premarket after the company said late Tuesday it priced its upsized underwritten public offering of 6.5 million shares at $62 apiece for gross proceeds of about $403 million.FinancialThe State Street Financial Select Sector SPDR ETF (XLF) advanced 0.3%. Direxion Daily Financial Bull 3X Shares (FAS) was up 0.9%, while its bearish counterpart Direxion Daily Financial Bear 3X Shares (FAZ) was 0.8% lower.Morgan Stanley (MS) shares were up more than 2% pre-bell after the company posted higher Q1 earnings and revenue.TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) retreated 0.04%, and the iShares US Technology ETF (IYW) was flat, while the iShares Expanded Tech Sector ETF (IGM) was up 0.02%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) gained 0.02%, while the iShares Semiconductor ETF (SOXX) retreated by 0.5%.ASML Holding (ASML) shares were down more than 2% in premarket activity after the company reported higher Q1 earnings and sales.IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) advanced 0.1%, while the Vanguard Industrials Index Fund (VIS) gained 0.3% and the iShares US Industrials ETF (IYJ) was inactive.CommoditiesFront-month US West Texas Intermediate crude oil gained by 0.4% to reach $91.66 per barrel on the New York Mercantile Exchange. Natural gas advanced by 0.9% to $2.62 per 1 million British Thermal Units. The United States Oil Fund (USO) increased by 0.1%, while the United States Natural Gas Fund (UNG) was 1.1% lower.Gold futures for May were down by 0.3% at $4,834.40 an ounce on the Comex. Silver futures declined by 0.8% to $78.95 an ounce. SPDR Gold Shares (GLD) was 2.2% higher, and the iShares Silver Trust (SLV) advanced by 5.5%.

Dow JonesNasdaq CompositeS&P 500$ASML$BETH$BITO$DHT$EEM$EETH$EXI$FAS$FAZ$GLD$IBB$IGM$IGV$IPK$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$MS$PMR$QQQ$RTH$SLV$SOXX$SPY$STLA$SYRE$UNG$USO$VDC$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD
Sectors

Sector Update: Health Care Stocks Advance Late Afternoon

Health care stocks rose late Monday afternoon, with the NYSE Health Care Index up 0.2% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.3%.The iShares Biotechnology ETF (IBB) climbed 1.6%.In corporate news, Seer (SEER) shares jumped 12% after it confirmed Monday that it has received a non-binding and unsolicited offer from its shareholder Radoff-JEC Group to acquire all its outstanding Class A shares for $2.25 per share in cash plus a contingent value right.Revolution Medicines (RVMD) shares surged 40% after it said Monday the phase 3 trial of its experimental drug daraxonrasib to treat a type of pancreatic cancer met key goals.Spyre Therapeutics (SYRE) shares jumped 23% after the company said its SPY001 investigational treatment for moderate-to-severely active ulcerative colitis met its primary and key secondary endpoints in a phase 2 trial.Replimune (REPL) is facing "significant risk" related to its ongoing phase 3 trial of RP1 in melanoma after the US Food and Drug Administration rejected the company's biologics license application for the product candidate, Wedbush Securities said in a note. Wedbush downgraded its rating on Replimune to neutral from outperform, with a lower price target of $2 from $19. Replimune shares tumbled 63%.

$REPL$RVMD$SEER$SYRE
Wire

Top Midday Gainers

Spyre Therapeutics (SYRE) shares soared 29% after the company said Monday its SPY001 investigational treatment for moderate-to-severely active ulcerative colitis met its key targets in a phase 2 trial.Over 4.10 million shares traded intraday, versus a daily average of roughly 747,000.ImageneBio (IMA) reported Monday that its private placement with certain institutional investors is expected to result in gross proceeds of about $30 million to the company.Shares jumped 22%, with intraday trading volume catapulting to more than 17.5 million from a daily average of about 38,000.Price: $65.06, Change: $+13.77, Percent Change: +26.85%

$IMA$SYRE
Sectors

Sector Update: Health Care Stocks Softer Monday Afternoon

Health care stocks declined Monday afternoon, with the NYSE Health Care Index down 0.2% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.3%.The iShares Biotechnology ETF (IBB) added 0.8%.In corporate news, Replimune (REPL) is facing "significant risk" related to its ongoing phase 3 trial of RP1 in melanoma after the US Food and Drug Administration rejected the company's biologics license application for the product candidate, Wedbush Securities said in a note. Wedbush downgraded its rating on Replimune to neutral from outperform, with a lower price target of $2 from $19. Replimune shares tumbled 64%.Seer (SEER) shares jumped 12%. The company has received a non-binding proposal from the Radoff-JEC Group to acquire the company for $2.25 per share in cash plus a contingent value right, the latter said.Revolution Medicines (RVMD) shares surged 39% after it said Monday the phase 3 trial of its experimental drug daraxonrasib to treat a type of pancreatic cancer met key goals.Spyre Therapeutics (SYRE) shares jumped 28% after the company said its SPY001 investigational treatment for moderate-to-severely active ulcerative colitis met its primary and key secondary endpoints in a phase 2 trial.

$REPL$RVMD$SEER$SYRE
Wire

Wedbush Adjusts Price Target on Spyre Therapeutics to $80 From $65, Maintains Outperform Rating

Spyre Therapeutics, Inc (SYRE) has an average rating of buy and mean price target of $66.50, according to analysts polled by FactSet.Price: $63.57, Change: $+12.28, Percent Change: +23.94%

$SYRE

Showing 1-20 of 23

Track with the FINWIRES app suite